Last reviewed · How we verify
Dexketoprofen Trometamol + Thiocolchicoside
Dexketoprofen reduces pain and inflammation via COX inhibition, while thiocolchicoside relaxes muscles by modulating neuromuscular transmission and reducing spasticity.
Dexketoprofen reduces pain and inflammation via COX inhibition, while thiocolchicoside relaxes muscles by modulating neuromuscular transmission and reducing spasticity. Used for Acute musculoskeletal pain with muscle spasm, Back pain with muscle tension, Inflammatory pain conditions.
At a glance
| Generic name | Dexketoprofen Trometamol + Thiocolchicoside |
|---|---|
| Sponsor | Yuzuncu Yil University |
| Drug class | NSAID + muscle relaxant combination |
| Target | COX-1/COX-2 (dexketoprofen); GABA receptors and microtubule dynamics (thiocolchicoside) |
| Modality | Small molecule |
| Therapeutic area | Pain Management, Musculoskeletal Disorders |
| Phase | FDA-approved |
Mechanism of action
Dexketoprofen trometamol is the active S-enantiomer of ketoprofen, a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Thiocolchicoside is a semi-synthetic derivative of colchicine that acts as a muscle relaxant by stabilizing microtubules and modulating GABA receptors, reducing muscle spasm and pain transmission. The combination targets both inflammatory pain and muscle tension.
Approved indications
- Acute musculoskeletal pain with muscle spasm
- Back pain with muscle tension
- Inflammatory pain conditions
Common side effects
- Gastrointestinal upset (nausea, dyspepsia)
- Dizziness
- Headache
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: